Your prediction
Pluristem Therapeutics Inc. Stock
Our community identified positive and negative aspects for Pluristem Therapeutics Inc. stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Pluristem Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Pluristem Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pluristem Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pluristem Therapeutics Inc. | - | - | - | - | - | - | - |
| Enlivex Therapeutics Ltd. | 0.000% | -50.278% | 279.237% | 36.641% | 193.443% | -22.174% | -71.129% |
| Oramed Pharmaceuticals | -0.570% | 0.572% | -12.779% | 94.791% | 44.948% | 15.739% | -69.435% |
| Heron Therapeutics Inc. | 0.230% | 2.964% | 15.931% | -70.432% | -61.329% | -70.694% | -95.846% |